Genmab’s Acquisition: A Value Investor’s Paradox

The acquisition, priced at $8 billion in cold, unyielding cash, has been ratified by both corporate hierarchies. Genmab’s high priests of profit declared this union would “meaningfully accelerate” their pilgrimage toward a “wholly owned model,” a phrase that drips with the irony of modern corporatist dogma. The deal’s consummation, expected in the first quarter of 2026, promises to “diversify revenue streams” and “drive sustained growth”-mantras chanted since time immemorial in the temple of shareholder value.








